ReviewMarine drugs2020
Genome Mining as New Challenge in Natural Products Discovery.
Review in Marine drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Emerging Therapeutic Potential of Fisetin for Nephrotoxicity, Kidney Injury, and Nephropathy: A Systematic Review.Current diabetes reviews · 2026Pooled it
- Genome mining reveals an architecturally expanded pyoluteorin-associated biosynthetic gene cluster and a divergent flavin-dependent halogenase-like sequence in deep-sea Pseudomonas Aeruginosa from the Gulf of Guinea.Antonie van Leeuwenhoek · 2026Article
- Global Research Landscape and Thematic Evolution of Fungi-Derived Antimicrobials Against Methicillin-ResistantBiology · 2026Review
- The Computational Revolution in Natural Product Research: A Data-Driven Roadmap for Next-Generation Drug Development.Biology · 2026Review
- Complete genome sequence ofMicrobiology resource announcements · 2026Article
- Genomic insights into the biosynthetic capacity of the sponge-associated fungus Aspergillus puulaauensis Hmp-F48.BMC genomics · 2026Article
- Multidimensional mechanisms of natural products in modulating metabolic dysfunction-associated kidney disease: recent advances and future perspectives.Frontiers in pharmacology · 2026Review
- Exploration of inactive metabolic pathways in AntarcticIMA fungus · 2026Article
- Elucidation of the pramanicin biosynthetic pathway reveals a DUF2306 family membrane protein involved in terminal epoxidation.Frontiers in microbiology · 2026Article
- Democratized Discovery of Microsclerodermin F as an Immunophilin Ligand.Marine drugs · 2025Article
- Whole-Genome Sequencing and Biosynthetic Gene Cluster Analysis of Novel Entomopathogenic BacteriaBiology · 2025Article
- Characterization of natural therapeutic compounds producing novel bacterial strains isolated from Hyderabad, India.Scientific reports · 2025Article
- Insights into Natural Products from Marine-Derived Fungi with Antimycobacterial Properties: Opportunities and Challenges.Marine drugs · 2025Review
- A Review on Bacteriocin Extraction Techniques from Lactic Acid Bacteria.Probiotics and antimicrobial proteins · 2025Review
- Genome mining reveals the biosynthetic potential of a novel Lysinibacillus zambalensis sp. nov., isolated from a hyperalkaline spring.Archives of microbiology · 2025Article
- Genomic and morphological features of an Amazonian Bacillus thuringiensis with mosquito larvicidal activity.AMB Express · 2025Article
- Current Approaches for Genetic Manipulation ofBiotech (Basel (Switzerland)) · 2025Review
- Actinomycetes - The Repertoire of Diverse Bioactive Chemical Molecules: From Structures to Antibiotics.Current topics in medicinal chemistry · 2025Review
- From the depths of the Java Trench: genomic analysis of Priestia flexa JT4 reveals bioprospecting and lycopene production potential.BMC genomics · 2024Article
- Whole-Genome Profiling of Endophytic Strain B.L.Ns.14 fromMicroorganisms · 2024Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug discovery is based on bioactivity screening of natural sources, traditionally represented by bacteria fungi and plants. Bioactive natural products and their secondary metabolites have represented the main source for new therapeutic agents, used as drug leads for new antibiotics and anticancer agents. After the discovery of the first biosynthetic genes in the last decades, the researchers had in their hands the tool to understand the biosynthetic logic and genetic basis leading to the production of these compounds. Furthermore, in the genomic era, in which the number of available genomes is increasing, genome mining joined to synthetic biology are offering a significant help in drug discovery. In the present review we discuss the importance of genome mining and synthetic biology approaches to identify new natural products, also underlining considering the possible advantages and disadvantages of this technique. Moreover, we debate the associated techniques that can be applied following to genome mining for validation of data. Finally, we review on the literature describing all novel natural drugs isolated from bacteria, fungi, and other living organisms, not only from the marine environment, by a genome-mining approach, focusing on the literature available in the last ten years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.